137 related articles for article (PubMed ID: 23548465)
1. Dalteparin dosing in high-flux haemodialysis and haemodiafiltration.
Sridharan S; Berdeprado J; Sivalingam M; Farrington K
Nephron Clin Pract; 2012; 122(1-2):53-7. PubMed ID: 23548465
[TBL] [Abstract][Full Text] [Related]
2. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
Verhave G; Weijmer MC; van Jaarsveld BC
Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dalteparin during haemodialysis.
Nigten J; de Groot KA; Grootendorst DC; Koolen SL; Herruer MH; Schut NH
Nephron Clin Pract; 2013; 124(3-4):179-83. PubMed ID: 24401673
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
6. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin.
Sagedal S; Hartmann A; Osnes K; Bjørnsen S; Torremocha J; Fauchald P; Kofstad J; Brosstad F
Nephrol Dial Transplant; 2006 Feb; 21(2):444-9. PubMed ID: 16234293
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
Frank RD; Brandenburg VM; Lanzmich R; Floege J
Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
9. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study.
Rommers MK; Van der Lely N; Egberts TC; van den Bemt PM
Crit Care; 2006; 10(3):R93. PubMed ID: 16790078
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.
Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B
Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610
[TBL] [Abstract][Full Text] [Related]
12. The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis.
Sombolos KI; Fragia TK; Gionanlis LC; Veneti PE; Bamichas GI; Fragidis SK; Georgoulis IE; Natse TA
Hemodial Int; 2009 Jan; 13(1):43-7. PubMed ID: 19210277
[TBL] [Abstract][Full Text] [Related]
13. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin anticoagulation in paediatric home haemodialysis.
Lutkin M; Stronach L; Yadav P; Hothi DK
Pediatr Nephrol; 2018 Dec; 33(12):2337-2341. PubMed ID: 30173320
[TBL] [Abstract][Full Text] [Related]
15. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
Kessler M; Gangemi C; Gutierrez Martones A; Lacombe JL; Krier-Coudert MJ; Galland R; Kielstein JT; Moureau F; Loughraieb N
Hemodial Int; 2013 Apr; 17(2):282-93. PubMed ID: 22925178
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.
Sagedal S; Hartmann A; Sundstrøm K; Bjørnsen S; Brosstad F
Nephrol Dial Transplant; 2001 May; 16(5):987-93. PubMed ID: 11328905
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
Klingel R; Schaefer M; Schwarting A; Himmelsbach F; Altes U; Uhlenbusch-Körwer I; Hafner G
Nephrol Dial Transplant; 2004 Jan; 19(1):164-70. PubMed ID: 14671052
[TBL] [Abstract][Full Text] [Related]
19. A single dose of dalteparin effectively prevents clotting during haemodialysis.
Sagedal S; Hartmann A; Sundstrøm K; Bjørnsen S; Fauchald P; Brosstad F
Nephrol Dial Transplant; 1999 Aug; 14(8):1943-7. PubMed ID: 10462275
[TBL] [Abstract][Full Text] [Related]
20. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
